Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: A study of 90 patients

British Journal of Haematology

Volumn 112, Issue 1, 2001, Pages 118-126

  Schoch, Claudia ^a   Haferlach, Torsten ^a   Haase, Detlef ^b   Fonatsch, Christa ^c   Löffler, Helmut ^d   Schlegelberger, Brigitte ^d   Staib, Peter ^e   Sauerland, Maria Cristina ^f   Heinecke, Achim ^f   Büchner, Thomas ^f   Hiddemann, Wolfgang ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF KIEL   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

^f UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Acute myeloid leukaemia; Clinical trial; Complex aberrant karyotype; Cytogenetics; Prognosis

Indexed keywords

ARABINOSIDE; CYTARABINE; CYTOSINE; DAUNORUBICIN; MITOXANTRONE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CHROMOSOME ABERRATIONS; CYTARABINE; CYTOGENETIC ANALYSIS; DAUNORUBICIN; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MITOXANTRONE; PROGNOSIS; REMISSION INDUCTION; THIOGUANINE;

EID: 0035135876     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02511.x     Document Type: Article

References (46)

1. The clinical significance of karyotype in acute myelogenous leukemia
2. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group
3. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group
4. Prognostic significance of chromosomal abnormalities in acute nonlymphocytic leukemia: A study of 343 patients
5. Prognostic factors for selecting curative therapy for adult acute myeloid leukemia
6. Introduction: Acute leukemia: Recent advances
7. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype
8. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): Two multicenter studies of the German AML Cooperative Group
9. Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia; data from the AML Cooperative Group
10. Therapeutic outcome in AML is mainly determined by cytogenetics, LDH in serum, early response and, in poor risk subgroup, by intensified induction treatment
11. Hematopoietic growth factors in acute myeloid leukemia: Supportive and priming effects
12. Adult acute leukemia
13. Prognostic significance of karyotype in de novo adult acute myeloid leukemia
14. Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: A report on 283 cases
15. Karyotype in acute myeloblastic leukemia: Prognostic significance in a prospective study assessing bone marrow transplantation in first remission
16. Karyotype in acute myeloblastic leukemia: Prognostic significance for bone marrow transplantation in first remission: A European Group for Blood and Marrow Transplantation Study
17. Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26) or t(3;3)(q21;q26)
18. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission
19. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial
20. Acute leukemia treated with intensive chemotherapy in patients with a history of previous chemo- and/or radiotherapy: Prognostic significance of karyotype and preceding myelodysplastic syndrome
21. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry
22. More individual markers are necessary for patients with acute myeloid leukemia (AML). Does cytomorphology or cytogenetics define the biological entity?
23. High-dose cytosine arabinoside and mitoxantrone: A highly effective regimen in refractory acute myeloid leukemia
24. Cytogenetic subgroups of AML and outcome from high dose versus conventional dose ARA-C as part of double induction
25. Management of acute myeloid leukemia in elderly patients
26. Cytogenetic subgroups of acute myeloid leukemia (AML) differ significantly in proliferative activity, cytokine production and sensitivity to GM-CSF stimulation
27. Activity of thymidine kinase and of polymerase a as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia
28. Secondary chromosomal abnormalities in acute leukemias
29. Nonparametric estimation from incomplete observations
30. Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia
31. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study
32. Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): Final report of AML-11
33. Clinical significance of cytogenetics in acute myeloid leukemia
34. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia
35. Design and analysis of randomized clinical trials requiring prolonged observation of each patient
36. Treatment of acute nonlymphocytic leukemia: Use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens
37. Identification of a relatively favorable group within AML/MDS patients with chromosome 5 and/or 7 abnormalities
38. Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia
39. Long-term survival in acute myelogenous leukemia: A second follow-up of the Fourth International Workshop on Chromosomes in Leukemia
40. Application of myeloid growth factors in the treatment of acute myeloid leukemia
41. Clinical and molecular aspects of retinoid therapy for acute promyelocytic leukemia
42. p53 Mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies
43. Factors relating to the achievement of complete remission (CR) in younger patients with acute myeloid leukemia (AML) in the united kingdom medical research council (MRC) AML 10 trial
44. Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: Significance of expression of the multidrug resistance gene-1 (MDR1)
45. High-resolution chromosomes as an independent prognostic indicator in adult acute nonlymphocytic leukemia